Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001366976 | SCV001563302 | uncertain significance | Familial aplasia of the vermis; Meckel-Gruber syndrome | 2022-08-06 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 8 of the RPGRIP1L gene. It does not directly change the encoded amino acid sequence of the RPGRIP1L protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs778583149, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with RPGRIP1L-related conditions. ClinVar contains an entry for this variant (Variation ID: 1057906). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002499749 | SCV002789368 | uncertain significance | Joubert syndrome 7; Meckel syndrome, type 5; COACH syndrome 3 | 2021-12-28 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001826055 | SCV002085746 | uncertain significance | Familial aplasia of the vermis | 2020-06-06 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004733274 | SCV005367615 | uncertain significance | RPGRIP1L-related disorder | 2024-09-05 | no assertion criteria provided | clinical testing | The RPGRIP1L c.1029+3A>C variant is predicted to interfere with splicing. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.020% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |